Introduction
============

Convincing evidence continues to emerge from clinical trials that gene therapy is yielding therapeutic effects in patients suffering from a wide range of diseases.^[@bib1],[@bib2]^ In particular, liver-directed gene therapy is becoming a promising modality to obtain sustained hepatocyte-specific expression of secreted factors into the circulation. This has implications for other liver-borne genetic and complex diseases. Despite these successes, there have been concerns regarding the efficacy and safety of some gene delivery approaches. The major limiting factors are insufficient and/or transient transgene expression levels and inappropriate expression of the transgene in unwanted cell types. Higher vector doses are typically used in gene therapy clinical trials to improve therapeutic efficacy. However, this often triggers T-cell--mediated immune responses against the vector capsid antigens displayed by transduced cells, particularly hepatocytes, in the context of MHC class I.^[@bib3],[@bib4],[@bib5]^ This contributes to the elimination of the gene-modified cells and liver toxicity, resulting in short-term gene expression. Moreover, inadvertent transgene expression in antigen-presenting cells (APCs), increases the risk of untoward immune responses against the gene-modified hepatocytes and/or the therapeutic transgene product.^[@bib6],[@bib7]^ Hence, there is a need to generate improved gene therapy vectors allowing the use of lower and safer vector doses that enable sustained hepatocyte-specific expression of the therapeutic gene.

Typically, conventional methods of vector design rely on haphazard trial-and-error approaches whereby transcriptional enhancers are combined with promoters to boost expression levels. Though this can sometimes be effective,^[@bib6],[@bib8]^ it often results in non-productive combinations that result in either modest or no increased expression levels of the gene of interest in hepatocytes and/or loss of liver specificity.^[@bib6]^ An intrinsic bias associated with the design of gene therapy vectors is that it frequently relies on the *in vitro* characteristics of its regulatory elements in cell lines, which is usually not predictive of their *in vivo* performance.^[@bib6],[@bib9]^ Moreover, these conventional approaches in vector design do not take into account the importance of including evolutionary conserved regulatory motifs into the expression modules, which is particularly relevant for clinical translation.

*In silico* design offers unique opportunities to generate robust liver-specific gene therapy vectors and overcome some of the limitations of conventional gene therapy vector development. Though data-mining has been used to identify *cis*-regulatory modules (*CRMs*) and analyze expression patterns *in vivo*,^[@bib10],[@bib11]^ surprisingly however, this area of research remains largely unexplored in the context of vector development and gene therapy. To address this caveat and overcome some of the limitations of conventional vector design, we have developed and validated an alternative strategy to generate efficient, liver-specific gene therapy vectors using computational methods. In this study, we relied on a genome-wide *in silico* identification of *CRMs* that contained clusters of evolutionarily conserved transcription factor binding site (*TFBS*) motifs associated with robust hepatocyte-specific expression. We employed a comprehensive computational strategy that takes into account not only the over-representation of a given *TFBS* but also its context-dependent co-occurrence with other *TFBS*.^[@bib12]^ Such an approach has not yet been used to improve the performance of gene therapy vectors, which underscores the novelty of this study. This computational approach has broad implications for liver-directed gene therapy and allows for the use of lower and thus safer vector doses, while maximizing therapeutic efficacy in pre-clinical mouse models and in non-human primates. Furthermore, the validation of these liver-specific *CRMs* provides new insights into the molecular determinants underlying transcriptional control in hepatocytes.

Results
=======

Computational *de novo* design of liver-specific CRMs
-----------------------------------------------------

Rational *de novo* design of robust liver-specific gene therapy vectors relies on the identification of tissue-specific *CRMs* associated with high hepatocyte-specific expression. To identify these critical hepatocyte-specific *CRMs* (*i.e.*, *HS-CRMs*), we used a multi-step computational approach. This bio-informatics approach was originally used to identify *CRMs* associated with differential gene expression in response to *in vitro* stimuli.^[@bib12]^ In this study, we extended this computational approach to identify evolutionary conserved *CRMs* associated with highly expressed liver-specific promoters. One of the unique features of this computational strategy is that it takes into account the over-representation of a given *TFBS* and its context-dependent co-occurrence with other *TFBS* on a genome-wide scale.^[@bib12]^

A total of 14 different *HS-CRMs* were identified, ranging in size from 41 bp to 551 bp (**[Figure 1](#fig1){ref-type="fig"}** and **[Table 1](#tbl1){ref-type="table"}** and **Supplementary Figure S1 and Table S2**). The *HS-CRM* comprised putative binding sites for eight different TFs: HNF1α, C/EBP, LEF1, FOX, IRF, LEF1/TCF, Tal1β/E47, and MyoD. These *HS-CRMs* contain a "molecular signature" that represents a hallmark of highly expressed genes in the liver. We observed that most *HS-CRMs* contain multiple *TFBS* that are similar but the uniqueness of each *HS-CRM* is dictated by its specific arrangement of the TFBS. Since all *HS-CRMs* exhibited a high degree of phylogenetic conservation among 44 divergent species, this suggests a strong evolutionary selective pressure to maintain these particular *TFBS* combinations for high tissue-specific expression. Phylogenetic conservation also increases the likelihood that the performance of the *HS-CRMs* is preserved across species in the process of clinical translation.

*In vivo* validation of hepatocyte-specific CRMs
------------------------------------------------

We subsequently assessed the efficiency and specificity of these novel *HS-CRMs* in liver. We first expressed human clotting factor IX (hFIX) from a chimeric promoter, composed of a potent liver-specific minimal *transthyretin promoter* (*TTR*) in conjunction with the different *HS-CRM* (**[Figure 2a](#fig2){ref-type="fig"}**). We choose hydrodynamic delivery to screen the 14 different hepatocyte-specific cis-regulatory modules (*HS-CRMs*) since it allows for a rapid and reliable assessment of their *in vivo* performance, without having to produce AAV vectors for each of them. Only the best *HS-CRM* was then selected for a subsequent comprehensive characterization in an AAV vector context (see below). Semi-high throughput hydrodynamic transfection of these expression plasmids into C57BL/6 mice revealed that the large majority (*i.e.*, 85%) of the *de novo* designed *HS-CRMs* resulted in a significant increase in hFIX expression (**[Figure 3a](#fig3){ref-type="fig"}**). In particular, the most potent *HS-CRM8* resulted in a robust improvement in hFIX expression, yielding up to 2.5 µg/ml. We subsequently validated the *HS-CRM8* element in AAV9-based vectors in which the *hFIX* gene was driven from either a moderately active (*Palm*) (**[Figure 3b](#fig3){ref-type="fig"}**) or potent liver promoter (*TTR*) (**[Figure 3c](#fig3){ref-type="fig"}**). The *de novo* designed *HS-CRM8* element in the AAV vector resulted in a robust and sustained 100-fold increase in hFIX expression from the moderately active *Palm* promoter (*P* \< 0.0001) (5 × 10^11^ vg, **[Figure 3b](#fig3){ref-type="fig"}**). Moreover, this *HS-CRM8* element significantly improved hFIX expression seven- to tenfold (*P* \< 0.00005), even when a potent liver-specific promoter was used like *TTR* (**[Figure 3c](#fig3){ref-type="fig"}**), consistent with the increased hFIX expression after hydrodynamic transfection (**[Figure 3a](#fig3){ref-type="fig"}**). This resulted in stable therapeutic hFIX expression levels of about 100%, even at relatively low vector doses (5 × 10^9^ vg). The *HS-CRM8* element increased transcription from both *TTR* and *Palm* promoters (**Supplementary Figure S2a,b**). The increased hFIX antigen levels correlated strongly with the *FIX mRNA* levels (**Supplementary Figure S2c**). There was no significant difference in vector copy number in mice injected with the vectors with or without the *HS-CRM8* element (**Supplementary Figure S2d**). The vector copy number correlated with the vector doses.

The potency of the *HS-CRM8* element was subsequently evaluated through assessment of phenotypic correction in hemophilic FIX-deficient mice following a tail-clip injury. The treated mice survived the injury in contrast to naive controls, consistent with a significant dose-dependent reduction in blood loss (naive mice: 1,167 ± 215 µl; 5 × 10^9^ vg/mouse: 596 ± 92 µl (*P* \< 0.0005); 2 × 10^10^ vg/mouse: 495 ± 82 µl (*P* \< 0.00005). *hFIX mRNA* expression was restricted to the liver (**[Figure 3d](#fig3){ref-type="fig"}**,**[e](#fig3){ref-type="fig"}**), even upon administration of extremely high vector doses (3 × 10^12^ vg), despite the detection of viral genomes in non-hepatic tissues (*i.e.*, heart, spleen, muscle, etc.) (data not shown).

To further enhance hFIX expression from the *HS-CRM8-TTR-FIX* construct, we subsequently replaced *hFIX Intron A* with an *MVM intron* upstream of the *hFIX transgene* (**[Figure 2c](#fig2){ref-type="fig"}**) or its codon-optimized equivalent (hFIXco) (**[Figure 2d](#fig2){ref-type="fig"}**). Each of these changes led to a significant increase in hFIX expression (**[Figure 4a](#fig4){ref-type="fig"}**,**[b](#fig4){ref-type="fig"}**). This optimized *HS-CRM8-TTR-MVM-FIXco* construct was then packaged into scAAV for subsequent validation in a non-human primate model.

Preclinical validation of efficacy and safety in non-human primates
-------------------------------------------------------------------

The scAAV9-HS-CRM8-TTR-MVM-hFIXco vector was injected into two cynomolgus macaques (OUG6 and OBEV7) at a dose of 9 × 10^11^ vg/kg. There was a steady increase in the circulating hFIX protein in both animals that reached a peak by week 4, corresponding to 1,718 ng/ml and 885 ng/ml for OUG6 and OBEV7, respectively (**[Figure 5a](#fig5){ref-type="fig"}**). These levels correspond to therapeutic FIX levels in the 20--35% range of normal FIX levels. After a few weeks, the hFIX transgene expression began to decline (**[Figure 5a](#fig5){ref-type="fig"}**), which could be ascribed to the induction of anti-hFIX antibodies (**[Figure 5c](#fig5){ref-type="fig"}**,**[d](#fig5){ref-type="fig"}**), often seen in non-human primates following AAV liver gene transfer,^[@bib13],[@bib14]^ despite the use of liver-specific promoters. The AAV9 vector administration also triggered anti-AAV9 neutralizing antibodies (**[Figure 5b](#fig5){ref-type="fig"}**). Both animals had consistent coagulation parameters despite the occurrence of hFIX inhibitory antibodies (**Supplementary Figure S3**). This indicates that the anti-hFIX antibodies did not cross-react with the macaque FIX. The animals did not develop any adverse events or toxicity (**Supplementary Figures S4 and S5**). Human *FIX mRNA* expression was restricted to the liver whereas only background levels were apparent in any other organ or tissue tested (**[Figure 6a](#fig6){ref-type="fig"}**). This confirms the liver-specificity of the synthetic *in silico* designed *HS-CRM8-TTR* promoter, consistent with the mouse data (**[Figure 3d](#fig3){ref-type="fig"}**,**[e](#fig3){ref-type="fig"}**). The AAV9 vector resulted predominately in liver transduction though significant gene transfer was also apparent in heart, lungs, spleen, kidney and brain (**[Figure 6b](#fig6){ref-type="fig"}**).

One of our animals (OUG6) was euthanized due to unexpected complications unrelated to the gene therapy, which occurred after a surgical procedure to obtain a liver biopsy. We subsequently tried to eliminate the anti-hFIX inhibitors in the remaining animal (OBEV7) following, transient immunosuppression with cyclosporin (CsA) and Rituximab (Rtx). This led to a modest increase in circulating FIX levels (**[Figure 5a](#fig5){ref-type="fig"}**), consistent with a decrease in anti-hFIX antibodies (**[Figure 5c](#fig5){ref-type="fig"}**,**[d](#fig5){ref-type="fig"}**). This was consistent with the profound decrease in CD20^+^ B cells (**[Figure 5e](#fig5){ref-type="fig"}**), whereas the percentage of CD3^+^ T cells remained unaffected (**[Figure 5f](#fig5){ref-type="fig"}**). Unfortunately, only partial and transient immunosuppression could be achieved, since the animal refused to ingest CsA after the initial treatment. Transient immunosuppression also led to transient and partial decline in anti-AAV9 neutralizing antibodies (**[Figure 5b](#fig5){ref-type="fig"}**).

Discussion
==========

In this study, we have validated a computational approach to improve the performance of current gene therapy vectors. Our data provide evidence that evolutionary conserved clusters of TFBS motifs corresponding to hepatocyte-specific *CRMs* could be identified *in silico* that are strongly associated with robust liver-specific expression *in vivo*. We discovered that the selected *HS-CRMs* identified contain a "molecular signature" composed of *TFBS* clusters that represent a hallmark of highly expressed genes in the liver. We demonstrated that these *HS-CRMs* resulted in a substantial increase in transgene expression in the liver after gene therapy, while maintaining a high degree of tissue-selectivity. In particular, a significant 10- to 100-fold increase in gene expression could be obtained depending on the type of *HS-CRM* and promoter used. The increased protein expression levels were consistent with an increased transcriptional activity. We subsequently validated the potential of these hepatocyte-specific *HS-CRMs* in a clinically relevant therapeutic setting and demonstrated robust and sustained supra-physiologic expression levels of coagulation FIX following hepatic transduction with AAV vectors. The use of these potent *HS-CRMs* therefore allows for the use of lower and thus safer vector doses in gene therapy clinical trials, that may in turn reduce the risk of developing T-cell--mediated immune responses against the vector antigens displayed on the transduced target cells.^[@bib1],[@bib2],[@bib3],[@bib4],[@bib5]^ *In silico* vector design may therefore pave the way towards a more rational and comprehensive strategy for vector optimization with broad implications to improve the efficacy and safety of gene therapy. Indeed, we have confirmed the superiority of the *HS-CRM8* expression module for liver-directed gene therapy using other transgenes (*i.e.*, factor VIII, phenylalanine hydroxylase; ref. [@bib15] and data not shown) Another advantage of these *CRMs* is their small size so that they can be readily accommodated into viral vectors in conjunction with relatively large therapeutic transgenes. The use of hyper-active FIX transgenes can further enhance vector performance.^[@bib16],[@bib17]^

We subsequently validated the efficacy and safety of the AAV-FIX vectors containing the most potent *HS-CRM8* expression module in a non-human primate model. Systemic vector administration resulted in robust therapeutic FIX levels in the 20--35% range at clinically relevant vector doses (9 × 10^11^ vg/kg). This is consistent with the high vector copy number in the liver biopsies. Exhaustive safety testing revealed no significant adverse effects. The performance of our vector compared favorably with that of one of the most potent AAV vectors that was used in a clinical trial in patients suffering from severe hemophila B.^[@bib3]^ Subjects injected with 6 × 10^11^ vg/kg, comparable to the dose used in our primate study, resulted in \~1--3% FIX. In those subjects injected with higher vectors doses (*i.e.*, 2 × 10^12^ vg/kg), \~10% FIX could be obtained.^[@bib3]^ Previously, we had assessed the performance of the same clinical trial vector in cynomolgus macaques.^[@bib13]^ When calibrating the vector doses, it would appear that our current vector design is about tenfold more efficient. Since a human FIX transgene was employed, it is known that this could potentially evoke neutralizing and non-neutralizing anti-hFIX antibodies in non-human primate models.^[@bib13]^ This is consistent with our observations that anti-hFIX antibodies were detected in the recipients which accounted for the subsequent decline in FIX expression. This provided us with an opportunity to test whether we could restore FIX by transient immunosuppression using rituximab and CsA. FIX could be detected after immune-suppression, even up to nearly 2 years after gene transfer. This suggests that the FIX-transduced hepatocytes persisted long-term and that the short-term FIX expression was primarily due to a humoral immune response. Our results caution that rituximab by itself may not suffice to treat patients that develop inhibitory antibodies after gene therapy and that more complex combination therapies may be required to achieve optimal immune suppression.

In this study, we choose to employ AAV9 instead of AAV8. Previously, Gao *et al*. evaluated the relationship of phylogenetic relatedness of distinct AAV serotypes and serologic activity.^[@bib18]^ Polyclonal antisera generated against AAV2 cross-reacted to a lesser extent with AAV9 than with AAV8. Conversely, polyclonal antisera generated against AAV9 cross-reacted to a lesser extent with AAV2 than when the polyclonal antisera were generated against AAV8. These experiments suggest that it may be desirable to select AAV9 over AAV8 to overcome neutralization by pre-existing anti-AAV2 antibodies in human subjects, which represents an important bottleneck in clinical trials. Moreover, we choose to explore AAV9 since the bio-distribution had not systematically been analyzed in non-human primates. Finally, we had previously conducted a side-by-side comparison between AAV8 and AAV9 and found that AAV9 transduced the liver just as efficiently as AAV8 in mice.^[@bib19]^

The advantage of this particular computational approach used to identify the tissue-specific *CRMs* compared to other *in silico* approaches was discussed previously.^[@bib12]^ One particularly distinctive feature is that it identifies not only the *TFBS* that are over-represented in liver-specific *CRMs* but also allows for the identification of frequently co-occurring TFBS. Consequently, this *in silico* analysis is more comprehensive and allows for the identification of *TFBS* elements that tend to cluster together in *CRMs* of genes that are highly expressed in a given target tissue (*in casu* liver). It therefore takes into account the actual context-dependent *TFBS* interactions from a broad genome-wide perspective, instead of just relying on the over-representation of a single TFBS element.^[@bib12]^ Our previous studies had shown that the present computational approach was more reliable, compared to other data-mining strategies that typically rely solely on the over-representation of a given TFBS, regardless of its context. The current *in silico* strategy that defines the HS-CRMs has been further improved by taking into account cross-species evolutionary conservation of the *TFBS* clusters. This approach is more comprehensive and increases the likelihood that the superior performance of the *HS-CRMs* is maintained in patients undergoing gene therapy, consistent with the robust FIX levels obtained in the non-human primate model. In addition, this study goes beyond the initial description and validation of the algorithm^[@bib12]^ and establishes a *bona fide* causal relationship between the presence of these evolutionary conserved *TFBS* clusters and high liver-specific expression. In contrast, the previously published bioinformatics approach was applied in a different context and merely established correlations between TFBS clusters and differentially expressed genes following a given physiologic stimulus. However, that study did not provide direct proof of the impact of such TFBS clusters on gene expression levels. This study addresses this caveat by direct *in vivo* gene transfer, hereby providing experimental *in vivo* validation of the bioinformatics algorithm. Though the majority of *HS-CRMs* resulted in a significant increase in gene expression, a few elements had only limited impact. This suggests that other unknown factors may influence gene expression, such as the spacing between a given *HS-CRM* and the *promoter/TATA box* or epigenetic factors and chromatin remodeling. This study sets the stage to further refine the *in silico* analysis to improve gene therapy vectors. Moreover, the most potent *HS-CRM8* could be used in conjunction with other liver-specific promoters, beyond those characterized in this study.

This study has broad implications for the design of better gene therapy vectors that target different diseases. The same principle could be applied to other vectors^[@bib24]^ or to other organs, tissues or promoters, which we have validating experimentally in heart and skeletal muscle (Rincon MY, Sarcar S, Danso-Abeam D, Keyaerts M, Matrai J, Samara-Kuko E, *et al*. unpublished data). This may ultimately impact not only on the clinical translation of gene therapy but also on fundamental biological and transgenic studies that rely on the use of robust tissue-specific gene expression.

Materials and Methods
=====================

Extended methods are available in the **Supplementary Methods**. The accession numbers of the genes from which the hepatocyte-specific *CRMs* (*i.e.*, *HS-CRM1 to 14*) are derived are listed in **[Table 1](#tbl1){ref-type="table"}**.

***Identification of hepatocyte-specific CRMs.*** To identify the hepatocyte-specific (HS)-*CRMs* (**[Figure 1](#fig1){ref-type="fig"}** and **[Table 1](#tbl1){ref-type="table"}** and **Supplementary Figure S1 and Table S1**), we used a step-wise *in silico* strategy: (i) we first identified liver-specific genes that are highly expressed in the liver based on statistical analysis of micro-array expression data of normal human tissues;^[@bib20],[@bib21]^ (ii) we then extracted the corresponding promoter sequences up to 800 bp upstream of the transcriptional start site (*TSS*) from public databases (NCBI36/hg18 genome assembly); (iii) using the TRANSFAC database we subsequently mapped TFBS elements to these promoters. We then identified the tissue-specific CRM using a multidimensional scaling (MDS)/ differential distance matrix (DDM) approach, as described;^[@bib12]^ (iv) Finally, the cross-species conservation was taken into consideration to identify highly conserved *HS-CRMs.*

***Generation of CRM constructs.*** The different *HS-CRMs* (**[Table 1](#tbl1){ref-type="table"}** and **Supplementary Table S1**) were synthesized by conventional oligonucleotide synthesis and cloned upstream of the liver-specific minimal transthyretin (*TTR*) (**[Figure 2a](#fig2){ref-type="fig"}**) or paralemmin (*Palm*) promoters (**[Figure 2b](#fig2){ref-type="fig"}**), driving the expression of the *factor IX* (*FIX*) *mini-gene*.^[@bib9]^ Alternatively, the *TTR* promoter coupled to the *HS-CRM8* element was used to drive wild-type *FIX* (**[Figure 2c](#fig2){ref-type="fig"}**) or its codon-optimized counterpart (**[Figure 2d](#fig2){ref-type="fig"}**) in the context of a self-complementary (sc) AAV backbone.^[@bib22]^ These vectors also contained a minute virus of mice (*MVM*) *mini-intron*. Cloning details are available upon request.

***AAV vector production and purification.*** Hepatotropic AAV9 vectors were prepared and purified, as previously described.^[@bib19]^ AAV vectors were purified by cesium chloride gradient ultracentrifugation. Vector titers were determined by quantitative (q) PCR (see **Supplementary Methods**).

***Animal procedures.*** Wild-type or hemophilic mice^[@bib23]^ were transfected hydrodynamically with plasmids or injected intravenously with purified AAV9 vectors. hFIX antigen levels were assayed in citrated mouse plasma using a hFIX-specific enzyme-linked immunosorbent assay (ELISA). Hemophilic mice were subjected to a tail-clipping assay.^[@bib7],[@bib19]^ The scAAV9-HS-CRM8-TTR-MVM-hFIXco vector (**[Figure 2d](#fig2){ref-type="fig"}**) (9 × 10^11^ vg/kg) was intravenously injected in cynomolgus macaques. Animals were subjected to transient immune suppression by cyclosporine A (CsA) and rituximab treatment.^[@bib13]^ Immunological analysis, hFIX antigen, anti-AAV9 capsid IgG, anti-hFIX IgG and Bethesda assays are described in **Supplementary Methods**. Gene expression levels were evaluated by qRT-PCR and normalized to mRNA levels of the endogenous monkey *GAPDH* gene. Transduction efficiency was determined by qPCR and transgene copy numbers were determined as described previously.^[@bib19]^

[**SUPPLEMENTARY MATERIAL**](#sup1){ref-type="supplementary-material"} **Figure S1.** Nucleotide sequence of the HS-CRM elements (HS-CRM1 to HS-CRM14). **Figure S2.** Hepatic hFIX mRNA levels and AAV copy numbers following intravenous injection of AAV9-FIX vectors in C57/Bl6 mice (*n* = 3). **Figure S3.** Safety analysis of scAAV9-HS-CRM8-TTR-MVM-hFIXco gene therapy in non-human primates: analysis of coagulation parameters. **Figure S4.** Safety analysis of scAAV9-HS-CRM8-TTR-MVM-hFIXco gene therapy in non-human primates: analysis of hematological parameters. **Figure S5.** Safety analysis of scAAV9-HS-CRM8-TTR-MVM-hFIXco gene therapy in non-human primates: blood chemistry. **Table S1.** Evolutionary conserved *HS-CRMs* enriched in *TFBS* associated with high liver-specific expression. **Methods.**
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Nucleotide sequence of the HS-CRM elements (HS-CRM1 to HS-CRM14).
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Hepatic hFIX mRNA levels and AAV copy numbers following intravenous injection of AAV9-FIX vectors in C57/Bl6 mice (*n* = 3).
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Safety analysis of scAAV9-HS-CRM8-TTR-MVM-hFIXco gene therapy in non-human primates: analysis of coagulation parameters.
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Safety analysis of scAAV9-HS-CRM8-TTR-MVM-hFIXco gene therapy in non-human primates: analysis of hematological parameters.
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Safety analysis of scAAV9-HS-CRM8-TTR-MVM-hFIXco gene therapy in non-human primates: blood chemistry.
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Evolutionary conserved *HS-CRMs* enriched in *TFBS* associated with high liver-specific expression.
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![**Nucleotide sequence of the HS-CRM8 element located with the promoter of human Serpina1.** This *HS-CRM8* element is the most potent *HS-CRM* that was identified by the hydrodynamic transfection screen (see **[Figure 3](#fig3){ref-type="fig"}**). The evolutionary conservation is highlighted and the *TFBS* are shown. The *TFBS* include binding sites for LEF-1 (brown), LEF-1/TCF (dark green), CEBP (yellow), FOXA1 (light blue), HNF1 (light green), and MyoD (purple).](mt2014114f1){#fig1}

![**Schematic representation of vectors used.** (**a**) AAV9-HS-CRM-TTR-FIX, (**b**) AAV9-HS-CRM-PALM-FIX, (**c**) AAV9-HS-CRM8-TTR-FIX, and (**d**) AAV9-HS-CRM8-TTR-FIXco. The expression cassettes in **a**--**b** were packaged in a single-stranded AAV9, flanked by the 5′ and 3′ AAV *inverted terminal repeats* (*ITR*). (**a**) The liver-specific *minimal transthyretin* (*TTR*) promoter drives the *human FIX minigene*. Alternatively, (**b**) a *Palm* (*paralemmin*) promoter was used that was only weakly expressed in liver to drive the *FIX mini-gene*. The hepatocyte-specific CRMs (*i.e.*, *HS-CRM1* to *HS-CRM14*) are located upstream of the (**a**) *TTR promoter*. Similarly, *HS-CRM8* is located upstream of the (**b**) *Palm* promoter. The *FIX first intron* (*intron A*) and *polyadenylation sites* (*pA*) are also indicated. The control vectors AAV9-TTR-FIX and AAV9-Palm-FIX are identical to AAV9-HS-CRM8-TTR-FIX and AAV9-HS-CRM8-Palm-FIX, respectively, except for the absence of any HS-CRM elements. The vectors (**c**) AAV9-HS-CRM8-TTR-FIX and (**d**) AAV9-HS-CRM8-TTR-FIXco were packaged in a self-complimentary AAV9. Both vectors had a small *MVM* (*minute virus of mice*) *intron* cloned upstream of the hFIX gene.](mt2014114f2){#fig2}

![***In vivo* validation of *HS-CRMs*.** (**a**) Semi-high throughput *HS-CRM* screening *in vivo* after intravenous hydrodynamic liver-directed injection with *pAAV-HS-CRM-TTR-FIX* and *pAAV-TTR-FIX* plasmids at a dose of 2 µg *DNA*. Significant differences compared to the control without *HS-CRM* were indicated (*t*-test, \**P* ≤ 0.05, mean ± SD). (**b**) FIX expression levels after intravenous administration of AAV9-HS-CRM8-Palm-FIX and AAV9-Palm-FIX (1 × 10^11^ vg/mouse) (*n* = 5 per cohort, C57Bl/6). The difference in FIX expression levels was significant (*t*-test, \**P* ≤ 0.0001). (**c**) FIX expression levels after intravenous administration of AAV9-HS-CRM8-TTR-FIX and AAV9-TTR-FIX control vectors (5 × 10^9^ vg/mouse) (*n* = 5 per cohort, C57Bl/6). The difference in FIX expression levels was significant (*t*-test, \**P* ≤ 0.00005). FIX levels were determined using a hFIX-specific ELISA. (**d**) Hepatocyte-specificity of AAV9 containing *HS-CRM8*. RT-PCR analysis on 20 ng total RNA from different organs of C57/Bl6 mice (*n* = 3) injected intravenously with AAV9-HS-CRM8-TTR-FIX vectors (3 × 10^12^ vg/mouse); RNA liver samples were amplified with and without RT to exclude genomic DNA amplification. Amplification of *hFIX mRNA* was not detectable in these control samples without RT (data not shown). (**e**) Corresponding qRT-PCR analysis of *hFIX mRNA* levels in the different organs expressed relative to *hFIX mRNA* levels in the liver. Expression levels (mean ± SD) relative to liver are shown. H~2~O, water control; MW, molecular weight marker; PBS liver, liver sample of PBS-injected control mice; RT, reverse transcription.](mt2014114f3){#fig3}

![**Optimization of the *HS-CRM8-TTR-hFIX* construct.** The (**a**) *pAAV-HS-CRM8-TTR-MVM-hFIX* or (**b**) *pAAV-HS-CRM8-TTR-FIXIA* and (**a**,**b**) *pAAV-HS-CRM8-TTR-MVM-hFIXco plasmids* were hydrodynamically transfected into C57BL/6 mice at doses of (**a**) 2 µg/mouse or (**b**) 0.5 µg/mouse. FIX expression was measured using a hFIX-specific ELISA (*n* = 4) on plasma samples collected 1 or 2 days after transfection (\*\**P* \< 0.01; \*\*\**P* \< 0.001).](mt2014114f4){#fig4}

![**Preclinical validation of efficacy and safety in non-human primates.** The scAAV9-HS-CRM8-TTR-MVM-hFIXco vector was injected in two cynomolgus macaques at a dose of 9 × 10^11^ vg/kg. (**a**) hFIX antigen expression, (**b**) anti-AAV9 capsid antibodies, and (**c**) anti-hFIX antibodies were measured by ELISA. (**b**) The drop in anti-AAV9 IgG during the immunosuppressive treatment corresponded to a drop in anti-AAV9 neutralization titer (from 1:1,000 to 1:316). (**d**) Inhibitor anti-hFIX antibodies were determined using Bethesda assays. The effect of the immunosuppressive regimen was monitored by determining the percentage of (**e**) CD20^+^ B cells and (**f**) CD3^+^ T cells. Open circles: animal OBEV7; filled squares: animal OUG6; gray area between dashed lines: cyclosporine A (CsA) administration; dotted line: rituximab (Rtx) administration.](mt2014114f5){#fig5}

![**Expression biodistribution and transduction efficiency analysis in non-human primates.** (**a**) Expression was analyzed by qRT-PCR and (**b**) biodistribution and transduction efficiency in different organs was determined by qPCR. Background signals from non-injected animals were subtracted from the experimental values.](mt2014114f6){#fig6}

###### *TFBS* strongly associated with high liver-specific expression
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